Get startedLog in
    Picture of Kalvista Pharmaceuticals logo

    KALV — Kalvista Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapMomentum Trap
    All News

    Brief: Kalvista Pharmaceuticals Announces Inclusion Of Ekterly® As A First-Line Therapy

    Picture of Kalvista Pharmaceuticals logoKalvista Pharmaceuticals
    18/02/2026 12:27
    Feb 18 (Reuters) - Kalvista Pharmaceuticals Inc KALV.O:

KALVISTA PHARMACEUTICALS ANNOUNCES INCLUSION OF EKTERLY® (SEBETRALSTAT) AS A FIRST-LINE THERAPY FOR ADOLESCENTS 12 AND OLDER IN INTERNATIONAL PEDIATRIC HAE GUIDELINE

KALVISTA PHARMACEUTICALS INC - ADVANCING KONFIDENT-KID TRIAL, PLANS DRUG APPLICATION FOR SEBETRALSTAT IN PATIENTS AGED 2 TO 11 IN Q3 2026

Source text: ID:nBw38H09fa

Further company coverage: KALV.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Kalvista Pharmaceuticals

    See all news